Sinovac Gives Details on Strong 2009 Results

Sinovac Biotech (北京科兴生物制品有限公司), the Beijing biopharma whose flu vaccines suddenly became very profitable in the second half of last year, released its 2009 financial results this week. Revenues for the fourth quarter almost tripled, rising 194% to $36.4 million, and sales for the full year rose 81% to $84.2 million. Net income for 2009 climbed 149% to $20 million or 46 cents per share, fully diluted. More details... Stock Symbol: (NSDQ: SVA)